PCRX on Nasdaq

Pacira BioSciences, Inc.

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Amphastar Pharmaceuticals, Inc., SUPERNUS PHARMACEUTICALS, INC. or Emergent BioSolutions, or pick any stock.

  • TickerPCRX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBrisbane, California1
  • Incorporated inDE2
  • Business address2000 Sierra Point Parkway, Suite 900, Brisbane, Ca 940052
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Pacira BioSciences, Inc., a Delaware corporation, is the holding company for our California operating subsidiary named Pacira Pharmaceuticals, Inc. In March 2007, we acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings, Inc. (now Vectura Group Limited, a subsidiary of Molex Asia Holdings, Ltd.), or Skyepharma (the “Skyepharma Acquisition”). In April 2019, we acquired MyoScience, Inc., a privately held medical technology company (the “MyoScience Acquisition”), in November 2021, we acquired Flexion Therapeutics, Inc., or Flexion, a publicly traded biopharmaceutical company (the “Flexion Acquisition”) and in February 2025, we acquired GQ Bio Therapeutics GmbH, or GQ Bio, a privately-held biopharmaceutical company (the “GQ Bio Acquisition”). Unless the context requires otherwise, references to “Pacira,” “we,” the “Company,” the “Registrant,” “us” and “our” in this Annual Report ref…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

2.6%Operating margin4
1.0%Net margin4
3.6%Revenue growth, 20254
1.0%Return on equity4
0.54×Debt to equity4
$136.7MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Exparel brought in 79% of the revenue Pacira BioSciences, Inc. broke down this way in fiscal 2025.

  1. Exparel$575.1M479%up 5% from 2024
  2. Zilretta$116.6M416%down 1% from 2024
  3. iovera$24.2M43%up 6% from 2024
  4. Bupivacaine Liposome Injectable Suspension$6.9M41%down 6% from 2024
  5. Royalty$3.6M40%down 6% from 2024
Products and services by year
Products and services202320242025
Exparel$538.1M$549.0M$575.1M
Zilretta$111.1M$118.1M$116.6M
iovera$19.7M$22.8M$24.2M
Bupivacaine Liposome Injectable Suspension$3.3M$7.3M$6.9M
Royalty$2.7M$3.8M$3.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue21¢$149.7M
  • Research and development16¢$117.3M
  • Selling, general and admin51¢$368.8M
  • Other costs10¢$73.7M
  • Income tax1¢$9.8M
  • Profit1¢$7.0M

Out of $726.4M in revenue.4

Where each dollar of operating cash went, fiscal 2025

  • Capital spending9¢$15.3M
  • Share buybacks91¢$148.3M

Out of $152.0M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.4

Financial statements

Revenue5674$726.4M in 2025+73% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $418.9M$418.9M20192020: $429.6M$429.6M2020+3%2021: $541.5M$541.5M2021+26%2022: $666.8M$666.8M2022+23%2023: $675.0M$675.0M2023+1%2024: $701.0M$701.0M2024+4%2025: $726.4M$726.4M2025+4%
Operating income56784$19.2M in 2025+83% since 2019
-$100.0M-$50.0M0$50.0M$100.0M2019: $10.5M$10.5M20192020: $46.4M$46.4M2020+342%2021: $89.9M$89.9M2021+94%2022: $60.0M$60.0M2022−33%2023: $87.7M$87.7M2023+46%2024: -$73.4M-$73.4M20242025: $19.2M$19.2M2025
Net income56784$7.0M in 2025
-$100.0M0$100.0M$200.0M2019: -$11.0M-$11.0M20192020: $145.5M$145.5M20202021: $42.0M$42.0M2021−71%2022: $15.9M$15.9M2022−62%2023: $42.0M$42.0M2023+164%2024: -$99.6M-$99.6M20242025: $7.0M$7.0M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Total revenues$726.4M$701.0M$675.0M
Cost of goods sold$149.7M$170.4M$184.7M
Research and development$117.3M$81.6M$76.3M
Selling, general and administrative$368.8M$294.1M$269.4M
Amortization of acquired intangible assets$57.3M$57.3M$57.3M
Goodwill impairment$0$163.2M$0
Contingent consideration gains, acquisition-related expenses, restructuring and other$14.1M$7.7M-$352.0K
Total operating expenses$707.2M$774.3M$587.3M
Income (loss) from operations$19.2M-$73.4M$87.7M
Interest income$22.7M$19.7M$11.4M
Interest expense-$17.4M-$16.6M-$20.3M
(Loss) gain on early extinguishment of debt-$983.0K$7.5M-$16.9M
Other, net-$6.6M-$373.0K-$186.0K
Total other (expense) income, net-$2.3M$10.3M-$26.0M
Income (loss) before income taxes$16.9M-$63.1M$61.7M
Income tax expense-$9.8M-$36.5M-$19.7M
Net income (loss)$7.0M-$99.6M$42.0M
Basic net income (loss) per common share (in dollars per share)$0.16-$2.15$0.91
Diluted net income (loss) per common share (in dollars per share)$0.16-$2.15$0.89
Basic (in shares)44.6M shares46.2M shares46.2M shares
Diluted (in shares)45.0M shares46.2M shares52.0M shares

Compare Pacira BioSciences, Inc. with another company

Leadership

Who has led Pacira BioSciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David M. Stack2011–2023
  2. Frank D. Lee2024–now

Chair

  1. David M. Stack2014–2023

President

  1. David M. Stack2011–2015
  2. James S. Scibetta2015–2017
  3. Max Reinhardt2019–2023

Chief financial officer

  1. James S. Scibetta2011–2016
  2. Charles A. Reinhart Iii.2016–2024
  3. Shawn Cross2024–now

Chief operating officer

  1. Scott Braunstein2018
  2. Daryl Gaugler2022–2025
201520202025
Board members and other officers (39)

Former names

  • Pacira Pharmaceuticals, Inc.Nov 1, 2010 to Apr 9, 20192
  • PACIRA INCMar 13, 2008 to Nov 5, 20082
  • Blue Acquisition CorpApr 16, 2007 to Apr 16, 20072

Timeline

  1. Jan 4, 2024New chief executive Frank D. Lee becomes CEO12
  2. Feb 2, 2011New chief executive David M. Stack becomes CEO13

Filings

448 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 69 major events, 201 insider forms, 28 large holders, 130 other. The latest 20:

  1. Oct 13, 2026SCHEDULE 13D/A EDGAR
  2. Oct 9, 20264 EDGAR
  3. Oct 8, 2026144 EDGAR
  4. Oct 8, 2026SC14D9C EDGAR
  5. Oct 8, 20268-K EDGAR
  6. Aug 18, 20264 EDGAR
  7. Aug 17, 2026144 EDGAR
  8. Aug 7, 2026SCHEDULE 13G EDGAR
  9. Aug 4, 2026S-8 EDGAR
  10. Aug 4, 202610-Q 10-Q - PCRX - 06.30.2026 EDGAR
  11. Aug 4, 20268-K EDGAR
  12. Jun 30, 20268-K EDGAR
  13. Jun 12, 2026144 EDGAR
  14. Jun 12, 20264 EDGAR
  15. Jun 12, 20264 EDGAR
  16. Jun 12, 20264 EDGAR
  17. Jun 12, 20264 EDGAR
  18. Jun 12, 20264 EDGAR
  19. Jun 12, 20264 EDGAR
  20. Jun 12, 20264 EDGAR

The 448 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

117 open-market trades by officers, directors and large owners since October 2021: 7 buys and 110 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 17, 2026SLONIN JONATHANChief Medical OfficerSale3,040$23.23$70.6KForm 4
Jun 11, 2026RIKER LAURENSenior Vice President, FinanceSale6,115$23.50$143.7KForm 4
Jun 4, 2026WILLIAMS KRISTENChief Administrative OfficerSale10,259$22.27$228.5KForm 4
Apr 23, 2026Cross ShawnChief Financial OfficerSale12,941$25.16$325.6KForm 4
Apr 22, 2026Cross ShawnChief Financial OfficerSale1,500$25.01$37.5KForm 4
Apr 21, 2026Cross ShawnChief Financial OfficerSale2,845$25.01$71.2KForm 4
Apr 20, 2026Cross ShawnChief Financial OfficerSale7,714$25.14$193.9KForm 4
Mar 17, 2026SLONIN JONATHANChief Medical OfficerSale3,261$22.82$74.4KForm 4
Mar 17, 2026Froimson MarkDirectorSale500$21.81$10.9KForm 4
Feb 2, 2026RIKER LAURENSenior Vice President, FinanceSale4,000$20.81$83.2KForm 4
Feb 2, 2026WILLIAMS KRISTENChief Administrative OfficerSale13,137$20.53$269.7KForm 4
Jan 5, 2026RIKER LAURENSenior Vice President, FinanceSale1,416$24.24$34.3KForm 4
Dec 10, 2025Cross ShawnChief Financial OfficerSale9,104$25.14$228.9KForm 4
Dec 9, 2025Cross ShawnChief Financial OfficerSale15,896$25.03$397.9KForm 4
Nov 17, 2025SLONIN JONATHANChief Medical OfficerSale3,960$24.09$95.4KForm 4
Nov 10, 2025Cross ShawnChief Financial OfficerSale12,060$22.09$266.4KForm 4
Sep 4, 2025Ceesay AbrahamDirectorSale2,354$27.19$64.0KForm 4
Aug 7, 2025BIGAL MARCELODirectorSale4,912$23.67$116.3KForm 4
Jun 4, 2025RIKER LAURENSenior Vice President, FinanceSale5,578$26.21$146.2KForm 4
Jun 4, 2025WILLIAMS KRISTENChief Administrative OfficerSale14,376$26.24$377.2KForm 4

All 117 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.6,705,809$170.1M0.0%−29,534
Doma Perpetual Capital Management LLC2,777,794$70.5M16.4%No change
Vanguard Portfolio Management LLC2,406,238$61.0M0.0%−95,048
Dimensional Fund Advisors LP2,103,245$53.4M0.0%+42,648
State Street Corp2,059,977$52.3M0.0%+140,367
D. E. Shaw & Co., Inc.1,950,332$49.5M0.0%−32,392
Renaissance Technologies LLC1,733,801$44.0M0.1%−91,700
Vanguard Capital Management LLC1,691,571$42.9M0.0%−92,478
Goldman Sachs Group Inc1,527,129$38.7M0.0%−42,787
Geode Capital Management, LLC1,158,693$29.4M0.0%+14,873
Morgan Stanley1,144,654$29.0M0.0%−247,894
American Century Companies Inc1,018,093$25.8M0.0%+180,530
UBS Group AG920,217$23.3M0.0%+358,177
Impax Asset Management Group plc750,027$19.0M0.1%No change
Two Sigma Investments, LP724,604$18.4M0.0%+197,753
Charles Schwab Investment Management Inc690,786$17.5M0.0%−41,256
Gagnon Securities LLC608,617$15.4M3.0%−8,893
Wellington Management Group Llp563,458$14.3M0.0%+85,075
Northern Trust Corp526,782$13.4M0.0%+7,370
Bridgeway Capital Management, LLC411,373$10.4M0.2%No change
Deutsche Bank Ag\391,101$9.9M0.0%−576
Jefferies Financial Group Inc.370,092$9.4M0.1%+173,800
Hillsdale Investment Management Inc.362,700$9.2M0.2%+31,400
Gagnon Advisors, LLC352,637$8.9M5.7%No change
Jpmorgan Chase & Co346,697$8.7M0.0%+106,328

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

9 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
May 6, 2021Tom MalinowskiDemocratic, HouseBuy$1,001 - $15,000−126.7%Report
Apr 20, 2021Tom MalinowskiDemocratic, HouseBuy$1,001 - $15,000−129.3%Report
Jan 25, 2021Tom MalinowskiDemocratic, HouseBuy$1,001 - $15,000−148.7%Report
Jan 15, 2021Tom MalinowskiDemocratic, HouseBuy$1,001 - $15,000−156.1%Report
Nov 2, 2020Tom MalinowskiDemocratic, HouseBuy$1,001 - $15,000−164.6%Report
Sep 26, 2019Tom MalinowskiDemocratic, HouseBuy$15,001 - $50,000−168.7%Report
Aug 23, 2019Tom MalinowskiDemocratic, HouseBuy$1,001 - $15,000−171.5%Report
May 31, 2019Tom MalinowskiDemocratic, HouseBuy$15,001 - $50,000−196.9%Report
May 30, 2019Tom MalinowskiDemocratic, HouseBuy$15,001 - $50,000−194.9%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69